Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment

J. W. Marks, R. A. Baum, R. F. Hanson, T. Hersh, N. C. Hightower, H. Mekhjian, R. A. Schaefer, R. D. Soloway, J. L. Thistle, F. B. Thomas

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.

Original languageEnglish (US)
Pages (from-to)382-384
Number of pages3
JournalAnnals of Internal Medicine
Volume100
Issue number3
StatePublished - 1984
Externally publishedYes

Fingerprint

Chenodeoxycholic Acid
Gallstones
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Marks, J. W., Baum, R. A., Hanson, R. F., Hersh, T., Hightower, N. C., Mekhjian, H., ... Thomas, F. B. (1984). Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment. Annals of Internal Medicine, 100(3), 382-384.

Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment. / Marks, J. W.; Baum, R. A.; Hanson, R. F.; Hersh, T.; Hightower, N. C.; Mekhjian, H.; Schaefer, R. A.; Soloway, R. D.; Thistle, J. L.; Thomas, F. B.

In: Annals of Internal Medicine, Vol. 100, No. 3, 1984, p. 382-384.

Research output: Contribution to journalArticle

Marks, JW, Baum, RA, Hanson, RF, Hersh, T, Hightower, NC, Mekhjian, H, Schaefer, RA, Soloway, RD, Thistle, JL & Thomas, FB 1984, 'Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment', Annals of Internal Medicine, vol. 100, no. 3, pp. 382-384.
Marks JW, Baum RA, Hanson RF, Hersh T, Hightower NC, Mekhjian H et al. Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment. Annals of Internal Medicine. 1984;100(3):382-384.
Marks, J. W. ; Baum, R. A. ; Hanson, R. F. ; Hersh, T. ; Hightower, N. C. ; Mekhjian, H. ; Schaefer, R. A. ; Soloway, R. D. ; Thistle, J. L. ; Thomas, F. B. / Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment. In: Annals of Internal Medicine. 1984 ; Vol. 100, No. 3. pp. 382-384.
@article{708c37df69084df78b6466f3cfce98e5,
title = "Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment",
abstract = "During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14{\%} and 5{\%} of patients, respectively, and partial dissolution (> 50{\%}) in 27{\%} and 18{\%}. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50{\%}) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23{\%} and 16{\%} of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.",
author = "Marks, {J. W.} and Baum, {R. A.} and Hanson, {R. F.} and T. Hersh and Hightower, {N. C.} and H. Mekhjian and Schaefer, {R. A.} and Soloway, {R. D.} and Thistle, {J. L.} and Thomas, {F. B.}",
year = "1984",
language = "English (US)",
volume = "100",
pages = "382--384",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment

AU - Marks, J. W.

AU - Baum, R. A.

AU - Hanson, R. F.

AU - Hersh, T.

AU - Hightower, N. C.

AU - Mekhjian, H.

AU - Schaefer, R. A.

AU - Soloway, R. D.

AU - Thistle, J. L.

AU - Thomas, F. B.

PY - 1984

Y1 - 1984

N2 - During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.

AB - During the National Cooperative Gallstone Study, therapy with chenodiol, 750 or 375 mg/d, for 2 years resulted in confirmed, complete gallstone dissolution in 14% and 5% of patients, respectively, and partial dissolution (> 50%) in 27% and 18%. The present study was done to determine the frequency with which complete dissolution occurs in patients having partial dissolution of gallstones who receive additional therapy. Eighty-six of one hundred thirty-eight eligible patients continued to receive 750 mg/d (61 patients) or 375 mg/d (25 patients) of chenodiol for 1 year. Patients whose oral cholecystogram at the end of the year showed further (> 50%) dissolution continued to receive chenodiol (28 patients at 750 mg/d and 11 patients at 375 mg/d) for a second year (total duration of therapy, 4 years). A final oral cholecystogram was taken at the end of the fourth year. Complete dissolution occurred in 23% and 16% of patients receiving chenodiol, 750 or 375 mg/d, respectively, for an additional 1 or 2 years.

UR - http://www.scopus.com/inward/record.url?scp=0021328077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021328077&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 382

EP - 384

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -